BLACK WEEKSFlacoane −15% · kituri −10% · restul −5%cu codulLivrare gratuită în Germania de la 200 €

Această pagină a fost tradusă automat și poate conține erori. Sunteți vorbitor nativ? Ne bucurăm să primim feedbackul și corecturile dumneavoastră.Trimiteți feedback

The Peptide Desk The Peptide Desk
Tamoxifen (Nolvadex), fotografie produs

Raport de laborator

PDF
Testat
Testat
Tamoxifen (Nolvadex) 20mg × 100 Tabs
Laborator
Analiza Białek
Dată
October 2026
Rezultat
20.34 mg per tablet (20 mg label)
Nr. comandă
Parolă

Testat independent, verificabil cu parola direct la laborator.

PCT & AI

Tamoxifen (Nolvadex)

PCT & AI

Comandă

Preț unitar - Livrare gratuită în Germania de la 200 € în timpul Black Weeks
  • DHL cu urmărire
  • Ambalare discretă

4.6 din 5 pe Trustpilot73 recenzii

Pe scurt

Tamoxifen (Nolvadex) în cifre

Valorile principale din lexiconul nostru.

Articolul complet din lexicon
Class
SERMestrogen receptor modulator
Half-life
longseveral days
Use
Oraldaily
Sizes
10 to 20 mg2 sizes in the shop

Informații

Totul despre Tamoxifen (Nolvadex)

FAQ

Întrebări frecvente

Surse pentru fiecare răspuns: articolul din lexicon

Mai aveți o întrebare?

Scrieți-ne, echipa noastră vă ajută.

Is tamoxifen approved?

Yes. ChEMBL lists tamoxifen with phase 4 as the highest phase and first approval in 1977. ClinicalTrials.gov lists 685 trials with tamoxifen, almost all on breast cancer, as of 26 October 2026.

How well did tamoxifen prevent gynecomastia in the trial?

114 men received the antiandrogen bicalutamide for 48 weeks, plus placebo, tamoxifen or anastrozole. Gynecomastia developed in 73 percent on placebo, 10 percent on tamoxifen and 51 percent on anastrozole. Breast pain occurred in 39, 6 and 27 percent.

Why was anastrozole weaker?

Anastrozole lowers the production of estrogen, tamoxifen blocks the effect directly at the receptor in the breast gland. In the trial anastrozole did not significantly reduce gynecomastia. A meta-analysis of 9 trials also found no significant benefit for anastrozole.

What does the meta-analysis show?

Nine randomised trials in men on bicalutamide were included. Tamoxifen lowered the risk of gynecomastia and breast pain by 82 percent (relative risk 0.18). Breast radiotherapy lowered the risk of gynecomastia by 52 percent.

Are there data on gynecomastia of unknown cause?

A breast clinic followed 81 men who received tamoxifen over 10 years. In 90.1 percent the gynecomastia resolved completely. There was no control group, so the evidence is limited.

What happened to the hormones?

Testosterone rose in all groups. With tamoxifen free testosterone stayed the same because the binding protein SHBG rose. Adverse events were not more common with tamoxifen than without (35 versus 37 percent).

Comparații

Cum se compară

Produse asemănătoare

Produse similare